Bristol-Myers Squibb (BMY) Shares Pop as Ipilimumab Reaches Primary Endpoint
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) shares are popping after-hours today following an announcement that ipilimumab clinical trial met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Shares are up 4.9% post-market.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb Co. (BMY) PT Raised to $65 at HSBC
- Openai Is Open To Slowing Cutting-edge Ai, Altman Tells Staff - Bloomberg
- Stellantis CEO: cost savings to ramp up in Q4
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
